CDK4/6 inhibitor: clinical trials recruiting now
6
Recruiting trials
3
Conditions studied
0
US states with sites
1
Countries
Phase breakdown
Phase 2 3
Phase 3 1
Not applicable 2
Conditions being studied
| Condition | Trials |
|---|---|
| Breast Cancer · CDK4/6 inhibitor for Breast Cancer | 6 |
| Advanced Breast Cancer | 2 |
| HR+/HER2- Breast Cancer | 1 |
Recruiting trials involving CDK4/6 inhibitor
- A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
- Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
- An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
- Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
- CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Common questions
How many recruiting trials involve CDK4/6 inhibitor?
6 recruiting trials across 3 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.